A clinical and correlative study of elotuzumab, carfilzomib, lenalidomide and dexamethasone (Elo-KRd) for lenalidomide refractory multiple myeloma in first relapse

Treatment of patients with multiple myeloma (MM) in first relapse remains a challenge. This phase II study combined elotuzumab (Elo) with carfilzomib, lenalidomide and dexamethasone (KRd) for treatment of MM in first relapse with the aim of improving efficacy.

Source: Clinical Lymphoma, Myeloma and Leukemia - April 6, 2023 Category: Hematology Authors: Manisha Bhutani, David M Foureau, Myra Robinson, Fei Guo, Kateryna Fesenkova, Shebli Atrash, Barry Paul, Cindy Varga, Reed Friend, Mauricio Pineda-Roman, Katherine Rigby, James T. Symanowski, Sarah Norek, Mallory R Tucker, Lawrence J Druhan, Peter M. Voor Source Type: research